Skip to main content
Clinical Trials/CTRI/2024/08/072499
CTRI/2024/08/072499
Not yet recruiting
Phase 2

Evaluation of efficacy and safety of adjuvant Pentoxifylline therapy in adults with community acquired pneumonia: An Open label, Randomized-controlled trial. - NI

SARANDEV A T V0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: J189- Pneumonia, unspecified organism
Sponsor
SARANDEV A T V
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
SARANDEV A T V

Eligibility Criteria

Inclusion Criteria

  • 1\)At least one acute clinical sign compatible with pneumonia (dyspnea, cough, purulent sputum, crackles)
  • 2\)Infiltrate on chest X\-ray or CT scan suggestive of pneumonia
  • 3\)Diagnosis of CAP at or during the 48 hours post\-hospital admission.
  • 4\)Informed consent signed by the patient, his/her legally authorized representative.

Exclusion Criteria

  • 1\)Patient on invasive mechanical ventilation.
  • 2\)Patients with creatinine clearance less than 30 ml per minute
  • 3\)Patient on vasopressors at the time of inclusion
  • 4\)Any contraindications to the study drug
  • 5\)Patient requiring corticosteroids (except for nebulized corticosteroids) for any reason.
  • 6\)Patient treated with antibiotics for more than 7 days prior to admission.
  • 7\)Suspicion of aspiration or heath care associated pneumonia.
  • 8\)Active tuberculosis
  • 9\)On immunosuppressive therapy or malignancy
  • 10\)Pregnancy or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials